[go: up one dir, main page]

CN107868039A - A kind of shellfish Qu Shaban intermediate Ns(5- chloro-2-pyridyls)- 2-(4- cyanobenzoyls)Amino ] -5- methoxy benzamides preparation method - Google Patents

A kind of shellfish Qu Shaban intermediate Ns(5- chloro-2-pyridyls)- 2-(4- cyanobenzoyls)Amino ] -5- methoxy benzamides preparation method Download PDF

Info

Publication number
CN107868039A
CN107868039A CN201711254533.2A CN201711254533A CN107868039A CN 107868039 A CN107868039 A CN 107868039A CN 201711254533 A CN201711254533 A CN 201711254533A CN 107868039 A CN107868039 A CN 107868039A
Authority
CN
China
Prior art keywords
compound
preparation
amino
chloro
sodium
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201711254533.2A
Other languages
Chinese (zh)
Inventor
刘海伦
常月赏
胡发红
金鑫
陈国华
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
China Pharmaceutical University
Original Assignee
China Pharmaceutical University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by China Pharmaceutical University filed Critical China Pharmaceutical University
Priority to CN201711254533.2A priority Critical patent/CN107868039A/en
Publication of CN107868039A publication Critical patent/CN107868039A/en
Pending legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D213/00Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72Nitrogen atoms
    • C07D213/75Amino or imino radicals, acylated by carboxylic or carbonic acids, or by sulfur or nitrogen analogues thereof, e.g. carbamates

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pyridine Compounds (AREA)

Abstract

本发明公开了贝曲沙班中间体N‑(5‑氯‑2‑吡啶基)‑2‑[(4‑氰基苯甲酰基)氨基]‑5‑甲氧基苯甲酰胺的制备方法。本发明采用如下技术方案,包括以下步骤:①5‑甲氧基‑2‑硝基苯甲酸(1)与三氯氧磷氯代,再与2‑氨基吡啶经酰胺化得到化合物2;②化合物2经催化氢化得到化合物3;③化合物3与对氰基苯甲酰氯缩合得到化合物4;④化合物4经氯代得到化合物5,总收率为57.2%,其主要优点是物料易得、操作简便、成本较低,且减少了副产物的产生,有利于工业化生产。 The invention discloses a preparation method of betrixaban intermediate N-(5-chloro-2-pyridyl)-2-[(4-cyanobenzoyl)amino]-5-methoxybenzamide. The present invention adopts the following technical scheme, comprising the following steps: ① chlorination of 5-methoxy-2-nitrobenzoic acid (1) with phosphorus oxychloride, and then amidation with 2-aminopyridine to obtain compound 2; ② compound 2 Compound 3 was obtained through catalytic hydrogenation; 3. compound 3 was condensed with p-cyanobenzoyl chloride to obtain compound 4; 4. compound 4 was chlorinated to obtain compound 5 with a total yield of 57.2%. The cost is low, and the generation of by-products is reduced, which is beneficial to industrial production.

Description

一种贝曲沙班中间体N-(5-氯-2-吡啶基)-2-[(4-氰基苯甲酰 基)氨基]-5-甲氧基苯甲酰胺的制备方法A kind of betrixaban intermediate N-(5-chloro-2-pyridyl)-2-[(4-cyanobenzoyl) Base) amino] the preparation method of-5-methoxybenzamide

技术领域technical field

本发明涉及一种贝曲沙班中间体N-(5-氯-2-吡啶基)-2-[(4-氰基苯甲酰基)氨基]-5-甲氧基苯甲酰胺的制备方法。The present invention relates to a preparation method of betrixaban intermediate N-(5-chloro-2-pyridyl)-2-[(4-cyanobenzoyl)amino]-5-methoxybenzamide .

背景技术Background technique

贝曲沙班(Betrixaban),化学名:N-(5-氯-2-吡啶基)-2-[[4-[(二甲氨基)亚氨基甲基]苯甲酰基]氨基]-5-甲氧基苯甲酰胺(6),是由波托拉制药公司开发的一种Xa因子高选择性抑制剂。贝曲沙班通过与Xa因子活性位点结合,使凝血酶原向凝血酶的转化受到抑制,并阻碍了纤维蛋白形成,从而有效抑制血栓的形成。该药物于2017年6月23日经FDA批准上市,商品名为Bevyxxa,用于预防急性发病但未行手术患者的静脉血栓栓塞和肺栓塞。Betrixaban (Betrixaban), chemical name: N-(5-chloro-2-pyridyl)-2-[[4-[(dimethylamino)iminomethyl]benzoyl]amino]-5- Methoxybenzamide (6) is a highly selective factor Xa inhibitor developed by Portola Pharmaceuticals. Betrixaban inhibits the conversion of prothrombin to thrombin by binding to the active site of factor Xa, and hinders the formation of fibrin, thereby effectively inhibiting the formation of thrombus. The drug was approved by the FDA on June 23, 2017, under the trade name Bevyxxa, for the prevention of venous thromboembolism and pulmonary embolism in patients with acute onset but no surgery.

N-(5-氯-2-吡啶基)-2-[(4-氰基苯甲酰基)氨基]-5-甲氧基苯甲酰胺是合成贝曲沙班的重要中间体,专利文献CN1391555A、WO0164643A2、WO2007056517A2、WO2008057972A1、US2010197929A1、CN101595092B、CN102762538A、CN104693114A、CN105732490A先后公开了贝曲沙班的制备方法。N-(5-chloro-2-pyridyl)-2-[(4-cyanobenzoyl)amino]-5-methoxybenzamide is an important intermediate for the synthesis of betrixaban, patent document CN1391555A , WO0164643A2, WO2007056517A2, WO2008057972A1, US2010197929A1, CN101595092B, CN102762538A, CN104693114A, CN105732490A successively disclosed the preparation method of betrixaban.

WO0164643A2报道了以5-甲氧基-2-硝基苯甲酸为起始原料,在三氯氧磷存在下,与2-氨基-5-氯吡啶反应,之后在经硫毒化的铂碳作用下加压氢化将硝基还原为氨基,所得氨基化合物与对氰基苯甲酰氯缩合,得到N-(5-氯-2-吡啶基)-2-[(4-氰基苯甲酰基)氨基]-5-甲氧基苯甲酰胺(5)。该方法中用到价格昂贵的硫化铂碳,造成生产成本增加,而且易导致吡啶环上5位氯被氢解,导致杂质增加。WO0164643A2 reported that 5-methoxy-2-nitrobenzoic acid was used as the starting material, reacted with 2-amino-5-chloropyridine in the presence of phosphorus oxychloride, and then reacted with platinum carbon poisoned by sulfur Pressurized hydrogenation reduces the nitro group to an amino group, and the resulting amino compound is condensed with p-cyanobenzoyl chloride to obtain N-(5-chloro-2-pyridyl)-2-[(4-cyanobenzoyl)amino] -5-methoxybenzamide (5). In this method, expensive platinum sulfide carbon is used, which increases the production cost and easily leads to the hydrogenolysis of the 5-position chlorine on the pyridine ring, resulting in an increase in impurities.

其中WO2008057972A1报道了类似合成路线,不同之处在于该专利利用二氯化锡对硝基进行还原,但该还原方法在反应过程中形成的杂质较多,不利于产物的分离,因此不利于工业化生产。CN104693114A报道了利用铁粉-醋酸体系对硝基进行还原,但反应过程需加入大量醋酸,且铁粉也是大大过量,从而导致大量废酸及铁泥,造成三废增多。Among them, WO2008057972A1 reported a similar synthetic route, the difference is that the patent uses tin dichloride to reduce the nitro group, but this reduction method forms more impurities during the reaction process, which is not conducive to the separation of products, so it is not conducive to industrial production . CN104693114A reports the use of iron powder-acetic acid system to reduce nitro groups, but the reaction process needs to add a large amount of acetic acid, and the iron powder is also in large excess, resulting in a large amount of waste acid and iron sludge, resulting in an increase in three wastes.

CN105732490A报道以5-甲氧基靛红酸酐为原料,在叔丁醇钾的作用下与2-氨基-5-氯吡啶发生反应,再与对氰基苯甲酰氯反应得到N-(5-氯-2-吡啶基)-2-[(4-氰基苯甲酰基)氨基]-5-甲氧基苯甲酰胺(5)。该路线虽然短,但起始原料5-甲氧基靛红酸酐不易得且价格昂贵,工艺中所形成的中间体存在游离的氨基,易与原料5-甲氧基靛红酸酐继续反应,形成杂质。CN105732490A report takes 5-methoxy isatoic anhydride as raw material, reacts with 2-amino-5-chloropyridine under the effect of potassium tert-butoxide, then reacts with p-cyanobenzoyl chloride to obtain N-(5-chloro -2-pyridyl)-2-[(4-cyanobenzoyl)amino]-5-methoxybenzamide (5). Although the route is short, the starting material 5-methoxyisatoic anhydride is not easy to obtain and is expensive. There are free amino groups in the intermediate formed in the process, which is easy to continue to react with the raw material 5-methoxyisatoic anhydride to form Impurities.

CN106518758报道了以5-甲氧基-2-氨基苯甲酸为起始原料,与苄醇发生酯化反应,再与对氰基苯甲酰氯反应,后经氢解脱苄得到游离的羧基,最后与2-氨基-5-氯吡啶反应形成N-(5-氯-2-吡啶基)-2-[(4-氰基苯甲酰基)氨基]-5-甲氧基苯甲酰胺(5)。该路线步骤繁琐,且氢解去苄基时氰基易被还原,使反应过程中杂质增加,从而不利于化合物5的分离纯化。CN106518758 has reported that with 5-methoxy-2-aminobenzoic acid as starting material, esterification reaction occurs with benzyl alcohol, then reacts with p-cyanobenzoyl chloride, and then obtains free carboxyl through hydrogenolysis debenzylation, and finally reacts with 2-Amino-5-chloropyridine is reacted to form N-(5-chloro-2-pyridyl)-2-[(4-cyanobenzoyl)amino]-5-methoxybenzamide (5). The steps of this route are cumbersome, and the cyano group is easily reduced during hydrogenolysis to remove the benzyl group, which increases the impurities during the reaction process, which is not conducive to the separation and purification of compound 5.

发明内容Contents of the invention

针对现有路线存在的问题,本发明提供了一种合成贝曲沙班中间体N-(5-氯-2-吡啶基)-2-[(4-氰基苯甲酰基)氨基]-5-甲氧基苯甲酰胺(5)的新方法,其路线如下:Aiming at the problems existing in the existing routes, the present invention provides a synthetic betrixaban intermediate N-(5-chloro-2-pyridyl)-2-[(4-cyanobenzoyl)amino]-5 -The new method of methoxybenzamide (5), its route is as follows:

以5-甲氧基-2-硝基苯甲酸(1)为起始原料,经三氯氧磷氯代,再与2-氨基吡啶经酰胺化得到化合物2,化合物2经催化氢化得到化合物3,化合物3与对氰基苯甲酰氯缩合得到化合物4,化合物4经氯代得到化合物5。Using 5-methoxy-2-nitrobenzoic acid (1) as the starting material, chlorination with phosphorus oxychloride, and amidation with 2-aminopyridine to obtain compound 2, and compound 2 to obtain compound 3 through catalytic hydrogenation , compound 3 was condensed with p-cyanobenzoyl chloride to obtain compound 4, and compound 4 was chlorinated to obtain compound 5.

步骤一:化合物1与三氯氧磷氯代,再与2-氨基吡啶经酰胺化得到化合物2。Step 1: Compound 1 is chlorinated with phosphorus oxychloride, and then amidated with 2-aminopyridine to obtain compound 2.

步骤二:化合物2经钯碳催化氢化得到化合物3。Step 2: compound 2 is hydrogenated by palladium carbon to obtain compound 3.

步骤三:化合物3与对氰基苯甲酰氯在碱性条件下缩合得到化合物4。Step 3: compound 3 is condensed with p-cyanobenzoyl chloride under basic conditions to obtain compound 4.

步骤四:化合物4经NCS氯代得到化合物5。Step 4: compound 4 was chlorinated by NCS to obtain compound 5.

作为上述技术方案的优选方案,步骤一中,化合物2的合成过程如下:取化合物1加入到乙腈中,滴加三氯氧磷,反应完全后加入2-氨基吡啶和吡啶,反应完全后滴加适量水,过滤,滤饼洗至中性,减压干燥得化合物2。As a preferred version of the above technical solution, in step 1, the synthesis process of compound 2 is as follows: take compound 1 and add it to acetonitrile, add phosphorus oxychloride dropwise, add 2-aminopyridine and pyridine after the reaction is complete, add dropwise Add appropriate amount of water, filter, wash the filter cake until neutral, and dry under reduced pressure to obtain compound 2.

进一步优选的,所述的化合物1、2-氨基吡啶、吡啶、三氯氧磷的摩尔比为1∶1∶(3~5)∶(1~2),其中吡啶为缚酸剂;所述的溶剂选自四氢呋喃、乙腈、苯、甲苯、二氯甲烷、乙酸乙酯、N,N-二甲基甲酰胺中的一种或几种组合,本发明优选溶剂为乙腈,化合物1与乙腈的质量体积比为1∶(10~15);酰化试剂选自三氯氧磷、三氯化磷、五氯化磷、二氯亚砜、三溴氧磷、三溴化磷、五溴化磷,本发明优选试剂为三氯氧磷。Further preferably, the molar ratio of compound 1, 2-aminopyridine, pyridine, and phosphorus oxychloride is 1:1:(3-5):(1-2), wherein pyridine is an acid-binding agent; The solvent is selected from one or more combinations of tetrahydrofuran, acetonitrile, benzene, toluene, methylene chloride, ethyl acetate, N, N-dimethylformamide, the preferred solvent of the present invention is acetonitrile, the compound 1 and acetonitrile The mass volume ratio is 1: (10-15); the acylating reagent is selected from phosphorus oxychloride, phosphorus trichloride, phosphorus pentachloride, thionyl chloride, phosphorus oxybromide, phosphorus tribromide, pentabromide Phosphorus, the preferred reagent of the present invention is phosphorus oxychloride.

作为上述技术方案的优选方案,步骤二中,化合物3的合成过程如下:取化合物2、钯碳加入到甲醇中,常压氢化,反应完全后过滤,减压浓缩得到化合物3。As a preferred version of the above technical solution, in step 2, the synthesis process of compound 3 is as follows: take compound 2 and palladium carbon and add them to methanol, hydrogenate at normal pressure, filter after the reaction is complete, and concentrate under reduced pressure to obtain compound 3.

进一步优选的,所述化合物2、钯碳的质量比为(15~20)∶1。Further preferably, the mass ratio of compound 2 to palladium on carbon is (15-20):1.

作为上述技术方案的优选方案,步骤三中,化合物4的合成过程如下:取化合物3、吡啶加入到二氯甲烷中,缓慢滴加4-氰基苯甲酰氯与二氯甲烷配成的溶液,反应完全后,洗涤分液,无水硫酸钠干燥,减压浓缩,得到化合物4。As a preferred version of the above-mentioned technical scheme, in step 3, the synthesis process of compound 4 is as follows: take compound 3 and pyridine and add it to dichloromethane, slowly add dropwise the solution made of 4-cyanobenzoyl chloride and dichloromethane, After the reaction was complete, the mixture was washed and separated, dried over anhydrous sodium sulfate, and concentrated under reduced pressure to obtain compound 4.

进一步优选的,所述溶剂选自水、四氢呋喃、二氧六环、乙腈、甲苯、二甲苯、苯、二氯甲烷、氯仿、四氯化碳、乙酸乙酯、乙酸丁酯、乙酸异丙酯、N,N-二甲基甲酰胺、N,N-二乙基乙酰胺、三乙胺、吡啶、二乙基异丙胺、丙酮、丁酮中的一种或几种组合,本发明优选二氯甲烷为溶剂。Further preferably, the solvent is selected from water, tetrahydrofuran, dioxane, acetonitrile, toluene, xylene, benzene, methylene chloride, chloroform, carbon tetrachloride, ethyl acetate, butyl acetate, isopropyl acetate , N, N-dimethylformamide, N, N-diethylacetamide, triethylamine, pyridine, diethylisopropylamine, acetone, butanone or one or more combinations, the present invention preferably two Chloromethane is the solvent.

进一步优选的,所用碱包括甲醇钠、乙醇钠、异丙醇钠、叔丁醇钾、叔丁醇钠、叔丁醇镁、氨基钠、氢化钠、氢化钙、氨水、三乙胺、吡啶、4-二甲氨基吡啶、二乙基异丙胺、DBU、苯胺、N,N-二甲基苯胺、N-甲基苯胺、碳酸钾、碳酸钠、碳酸铯、碳酸氢钠、碳酸氢钾、氢氧化钠、氢氧化钾、氢氧化钙,本发明优选为吡啶。Further preferably, the base used includes sodium methoxide, sodium ethoxide, sodium isopropoxide, potassium tert-butoxide, sodium tert-butoxide, magnesium tert-butoxide, sodium amide, sodium hydride, calcium hydride, ammonia, triethylamine, pyridine, 4-dimethylaminopyridine, diethylisopropylamine, DBU, aniline, N,N-dimethylaniline, N-methylaniline, potassium carbonate, sodium carbonate, cesium carbonate, sodium bicarbonate, potassium bicarbonate, hydrogen Sodium oxide, potassium hydroxide, calcium hydroxide, the present invention is preferably pyridine.

进一步优选的,化合物3和对氰基苯甲酰氯的摩尔比为1∶(1~2);反应温度为-10℃~40℃,本发明优选为20℃~30℃。Further preferably, the molar ratio of compound 3 to p-cyanobenzoyl chloride is 1:(1-2); the reaction temperature is -10°C to 40°C, preferably 20°C to 30°C in the present invention.

作为上述技术方案的优选方案,步骤四中,化合物5的合成过程如下:将化合物4、氯代试剂、引发剂加入到N,N-二甲基甲酰胺中,加热反应,反应完全后,加入二氯甲烷、水,洗涤分液,无水硫酸钠干燥,过滤,滤液减压浓缩,用四氢呋喃-乙醇混合溶剂重结晶,得到化合物5。As a preferred version of the above-mentioned technical solution, in step 4, the synthesis process of compound 5 is as follows: compound 4, chlorinated reagent, and initiator are added to N,N-dimethylformamide, and the reaction is heated. After the reaction is complete, add Dichloromethane and water were washed and separated, dried over anhydrous sodium sulfate, filtered, the filtrate was concentrated under reduced pressure, and recrystallized with tetrahydrofuran-ethanol mixed solvent to obtain compound 5.

进一步优选的,所述溶剂为N,N-二甲基甲酰胺、N,N-二甲基乙酰胺、N,N-二乙基甲酰胺、N,N-二乙基乙酰胺、二氯甲烷、三氯甲烷、四氯化碳、苯、甲苯、环戊烷、正戊烷、环己烷、正己烷、环庚烷、正庚烷、四氢呋喃、二氧六环、乙腈、水中的一种或几种组合,本发明优选N,N-二甲基甲酰胺为溶剂,且化合物4与N,N-二甲基甲酰胺的质量体积比为1∶(5~10)。Further preferably, the solvent is N,N-dimethylformamide, N,N-dimethylacetamide, N,N-diethylformamide, N,N-diethylacetamide, dichloro Methane, chloroform, carbon tetrachloride, benzene, toluene, cyclopentane, n-pentane, cyclohexane, n-hexane, cycloheptane, n-heptane, tetrahydrofuran, dioxane, acetonitrile, one in water In the present invention, N, N-dimethylformamide is preferred as the solvent, and the mass volume ratio of compound 4 to N, N-dimethylformamide is 1: (5-10).

进一步优选的,所述氯代试剂选自N-氯代琥珀酰亚胺、N-氯代邻磺酰苯甲酰亚胺、N-氯代酞酰亚胺、1,3-二氯-5,5-二甲基海因、1,3-二氯-5-甲基-5-乙基海因、氯气,本发明优选氯代试剂为N-氯代琥珀酰亚胺,且化合物4与N-氯代琥珀酰亚胺的摩尔比为1∶(1.0~2.0)。Further preferably, the chlorination reagent is selected from N-chlorosuccinimide, N-chloro-o-sulfonylbenzimide, N-chlorophthalimide, 1,3-dichloro-5 , 5-dimethylhydantoin, 1,3-dichloro-5-methyl-5-ethylhydantoin, chlorine, the preferred chlorination reagent of the present invention is N-chlorosuccinimide, and compound 4 and The molar ratio of N-chlorosuccinimide is 1: (1.0-2.0).

进一步优选的,所述引发剂为过氧苯甲酰、叔丁基过氧化氢、过氧环己酮、偶氮二异丁腈、偶氮二异庚腈中的一种或几种组合,本发明优选为过氧苯甲酰,且化合物4与过氧苯甲酰的摩尔比为1∶(0.05~0.1)。Further preferably, the initiator is one or more combinations of benzoyl peroxide, tert-butyl hydroperoxide, cyclohexanone peroxide, azobisisobutyronitrile, azobisisoheptanonitrile, The present invention is preferably benzoyl peroxide, and the molar ratio of compound 4 to benzoyl peroxide is 1: (0.05-0.1).

进一步优选的,所述反应温度为0℃~100℃,本发明优选70℃~80℃。Further preferably, the reaction temperature is 0°C to 100°C, preferably 70°C to 80°C in the present invention.

进一步优选的,所述反应时间为2h~8h,本发明优选为3h。Further preferably, the reaction time is 2h-8h, preferably 3h in the present invention.

进一步优选的,所述重结晶溶剂选自四氢呋喃、二氧六环、乙酸乙酯、甲醇、乙醇、正丙醇、异丙醇、正丁醇、二氯甲烷、正己烷、环己烷中的一种或几种组合,本发明优选溶剂为四氢呋喃和乙醇混合溶剂。Further preferably, the recrystallization solvent is selected from tetrahydrofuran, dioxane, ethyl acetate, methanol, ethanol, n-propanol, isopropanol, n-butanol, dichloromethane, n-hexane, cyclohexane One or several combinations, the preferred solvent of the present invention is a mixed solvent of tetrahydrofuran and ethanol.

与现有技术相比,本发明对贝曲沙班中间体N-(5-氯-2-吡啶基)-2-[(4-氰基苯甲酰基)氨基]-5-甲氧基苯甲酰胺的改进克服了诸多不足,总收率为57.2%,其主要优点是物料易得、操作简便、成本较低,且减少了副产物的产生,有利于工业化生产。Compared with the prior art, p-betrixaban intermediate N-(5-chloro-2-pyridyl)-2-[(4-cyanobenzoyl)amino]-5-methoxybenzene of the present invention The improvement of formamide overcomes many shortcomings, and the total yield is 57.2%. Its main advantages are that the material is easy to obtain, the operation is simple, the cost is low, and the generation of by-products is reduced, which is beneficial to industrial production.

具体实施方式Detailed ways

下列实例进一步说明本发明,但本发明并不受其限制。The following examples further illustrate the invention, but the invention is not limited thereto.

实施例:Example:

实施例1 化合物2的制备Example 1 Preparation of Compound 2

取化合物1(20g,102mmol)加入到150ml乙腈中,室温滴加三氯氧磷(23g,300mmol),加毕,反应完全后加入2-氨基吡啶(9.5g,101mmol)和吡啶(23.7g,300mmol),室温继续反应4h。缓慢滴加150ml水,过滤,滤饼用水洗至中性,50℃减压干燥得24.6g化合物2,产率98.04%。Get compound 1 (20g, 102mmol) and join in 150ml acetonitrile, dropwise add phosphorus oxychloride (23g, 300mmol) at room temperature, add, add 2-aminopyridine (9.5g, 101mmol) and pyridine (23.7g, 300mmol), the reaction was continued at room temperature for 4h. 150ml of water was slowly added dropwise, filtered, the filter cake was washed with water until neutral, and dried under reduced pressure at 50°C to obtain 24.6g of compound 2 with a yield of 98.04%.

实施例2 化合物3的制备Example 2 Preparation of Compound 3

取化合物2(16g,59mmol)、10%钯碳(1g)加入到300ml甲醇中,常压氢化,室温反应6h,过滤,将黄绿溶液减压浓缩,得13.6g化合物3,产率94.82%。1H NMR(500MHz,DMSO-d6)δ10.55(s,1H),8.46-8.32(m,1H),8.13(d,J=8.4Hz,1H),7.84(m,J=8.3,7.8,1.9Hz,1H),7.33(d,.J=2.9Hz,1H),7.23-7.07(m,1H),6.93(dd,J=8.9,2.9Hz,1H),6.78(d,J=8.9Hz,1H),6.00(s,2H),3.77(s,3H).Add compound 2 (16g, 59mmol) and 10% palladium carbon (1g) to 300ml of methanol, hydrogenate at normal pressure, react at room temperature for 6h, filter, and concentrate the yellow-green solution under reduced pressure to obtain 13.6g of compound 3 with a yield of 94.82% . 1 H NMR (500MHz, DMSO-d 6 ) δ10.55(s, 1H), 8.46-8.32(m, 1H), 8.13(d, J=8.4Hz, 1H), 7.84(m, J=8.3, 7.8 , 1.9Hz, 1H), 7.33(d, .J=2.9Hz, 1H), 7.23-7.07(m, 1H), 6.93(dd, J=8.9, 2.9Hz, 1H), 6.78(d, J=8.9 Hz, 1H), 6.00(s, 2H), 3.77(s, 3H).

实施例3 化合物4的制备Example 3 Preparation of compound 4

取化合物3(10g,41mmol)、吡啶5ml加入到100ml二氯甲烷中,室温缓慢滴加由4-氰基苯甲酰氯(8.16g,49mmol)与二氯甲烷10ml配制的溶液,加毕,室温继续反应3h,分别用80ml水、80ml饱和碳酸氢钠、80ml水洗涤,分液,无水硫酸钠干燥,滤液减压浓缩,得12.3g化合物4,产率80.62%。1H NMR(500MHz,DMSO-d6)δ 11.14(s,1H),10.91(s,1H),8.50-8.35(m,1H),8.18-7.96(m,6H),7.96-7.76(m,1H),7.49(d,J=2.9Hz,1H),7.21(m,J=7.5,4.2Hz,2H),3.90(s,3H).Take compound 3 (10g, 41mmol) and 5ml of pyridine and add it to 100ml of dichloromethane, slowly add dropwise at room temperature the solution prepared by 4-cyanobenzoyl chloride (8.16g, 49mmol) and 10ml of dichloromethane. The reaction was continued for 3 h, washed with 80 ml of water, 80 ml of saturated sodium bicarbonate, and 80 ml of water respectively, separated, dried over anhydrous sodium sulfate, and the filtrate was concentrated under reduced pressure to obtain 12.3 g of compound 4 with a yield of 80.62%. 1 H NMR (500MHz, DMSO-d 6 ) δ 11.14(s, 1H), 10.91(s, 1H), 8.50-8.35(m, 1H), 8.18-7.96(m, 6H), 7.96-7.76(m, 1H), 7.49(d, J=2.9Hz, 1H), 7.21(m, J=7.5, 4.2Hz, 2H), 3.90(s, 3H).

实施例4 化合物5的制备Example 4 Preparation of Compound 5

取化合物4(10g,27mmol)、NCS(3.6g,27mmol)、过氧苯甲酰(0.5g,2.1mmol)加入到N,N-二甲基甲酰胺(80ml)中,反应液升温至70℃~80℃并反应3h,冷却至室温,向反应液加入二氯甲烷(100ml)并分别用150ml饱和碳酸氢钠、150ml水洗涤,分液,无水硫酸钠干燥,滤液减压浓缩,所得残留物用70ml四氢呋喃-乙醇混合溶剂重结晶,得8.39g化合物5,产率76.38%。MS(ESI)m/z:[M+Na]+429.1,1H NMR(500MHz,DMSO-d6)δ 11.10(s,1H),11.03(s,1H),8.47(s,1H),8.15(d,J=9.0Hz,1H),8.05(q,J=8.2Hz,4H),8.00-7.93(m,2H),7.44(d,J=2.9Hz,1H),7.20(dd,J=8.9,2.8Hz,1H),3.88(s,3H).Get compound 4 (10g, 27mmol), NCS (3.6g, 27mmol), benzoyl peroxide (0.5g, 2.1mmol) and join in N,N-dimethylformamide (80ml), and the reaction solution is heated to 70 ℃~80℃ and reacted for 3h, cooled to room temperature, added dichloromethane (100ml) to the reaction solution and washed with 150ml saturated sodium bicarbonate and 150ml water respectively, separated, dried over anhydrous sodium sulfate, and the filtrate was concentrated under reduced pressure to obtain The residue was recrystallized with 70 ml of tetrahydrofuran-ethanol mixed solvent to obtain 8.39 g of compound 5 with a yield of 76.38%. MS (ESI) m/z: [M+Na] + 429.1, 1 H NMR (500 MHz, DMSO-d 6 ) δ 11.10 (s, 1H), 11.03 (s, 1H), 8.47 (s, 1H), 8.15 (d, J=9.0Hz, 1H), 8.05(q, J=8.2Hz, 4H), 8.00-7.93(m, 2H), 7.44(d, J=2.9Hz, 1H), 7.20(dd, J= 8.9, 2.8Hz, 1H), 3.88(s, 3H).

Claims (10)

1. one kind prepares shellfish Qu Shaban intermediate Ns (5- chloro-2-pyridyls) -2- [(4- cyanobenzoyls) amino] -5- methoxies The method of yl-benzamide, it comprises the following steps:
(1) under alkali effect, 5- methoxyl group -2- amino-N- (pyridine -2- bases) benzamides (3) to cyano-benzoyl chloride with contracting Conjunction obtains 2- [(4- cyanobenzoyls) amino] -5- methoxyl groups-N- (pyridine -2- bases) benzamide (4);
(2) 2- [(4- cyanobenzoyls) amino] -5- methoxyl groups-N- (pyridine -2- bases) benzamide (4) obtains shellfish through chloro Qu Shaban intermediate Ns (5- chloro-2-pyridyls) -2- [(4- cyanobenzoyls) amino] -5- methoxy benzamides (5).
2. method as claimed in claim 1, it is characterised in that:The preparation of the compound 4, solvent for use be water, tetrahydrofuran, Dioxane, acetonitrile, toluene, dimethylbenzene, benzene, dichloromethane, chloroform, carbon tetrachloride, ethyl acetate, butyl acetate, acetic acid are different Propyl ester, DMF, N, in N- diethyl acetamides, triethylamine, pyridine, diethylisopropylamide, acetone, butanone One or more combination, the present invention are preferably dichloromethane.
3. method as claimed in claim 1, it is characterised in that:The preparation of the compound 4, alkali used include sodium methoxide, ethanol Sodium, sodium isopropylate, potassium tert-butoxide, sodium tert-butoxide, tert-butyl alcohol magnesium, Sodamide, sodium hydride, calcium hydride, ammoniacal liquor, triethylamine, pyridine, DMAP, diethylisopropylamide, DBU, aniline, DMA, methylphenylamine, potassium carbonate, sodium carbonate, Cesium carbonate, sodium acid carbonate, saleratus, sodium hydroxide, potassium hydroxide, calcium hydroxide, the present invention are preferably pyridine.
4. method as claimed in claim 1, it is characterised in that:The preparation of the compound 4, compound 3 and to Cyanophenacyl The mol ratio of chlorine is 1: (1~2);Reaction temperature is -10 DEG C~40 DEG C, and the present invention is preferably 20 DEG C~30 DEG C.
5. method as claimed in claim 1, it is characterised in that:The preparation of the compound 5, chlorinating agent used in chlorination are Chloro- 5, the 5- dimethyl sea of N-chlorosuccinimide, N- chloros saccharin, N- chloros phthalimide, 1,3- bis- Cause, the chloro- 5- methyl -5- ethylhydantoins of 1,3- bis-, chlorine, the present invention preferably N-chlorosuccinimide, and compound 4 and N- The mol ratio of chlorosuccinimide is 1: (1.0~2.0).
6. method as claimed in claim 1, it is characterised in that:The preparation of the compound 5, initiator used are peroxide benzene first One or more combination in acyl, TBHP, peroxide cyclohexanone, azodiisobutyronitrile, ABVN, this hair Bright is preferably benzoyl peroxide, and compound 4 and the mol ratio of benzoyl peroxide are 1: (0.05~0.1).
7. method as claimed in claim 1, it is characterised in that:The preparation of the compound 5, solvent for use N, N- dimethyl methyl Acid amides, DMA, N, N- diethylformamides, N, N- diethyl acetamides, dichloromethane, chloroform, four Chlorination carbon, benzene, toluene, pentamethylene, pentane, hexamethylene, n-hexane, cycloheptane, normal heptane, tetrahydrofuran, dioxane, second One or more combination in nitrile, water, the present invention preferably DMF, and compound 4 and N, N- dimethyl methyl The mass volume ratio of acid amides is 1: (5~10).
8. method as claimed in claim 1, it is characterised in that:The preparation of the compound 5, reaction temperature are 0 DEG C~100 DEG C, The present invention is preferably 70 DEG C~80 DEG C.
9. method as claimed in claim 1, it is characterised in that:The preparation of the compound 5, reaction time are 2h~8h, this hair Bright is preferably 3h.
10. method as claimed in claim 1, it is characterised in that:The preparation of the compound 5, recrystallization solvent are selected from tetrahydrochysene furan Mutter, in dioxane, ethyl acetate, methanol, ethanol, normal propyl alcohol, isopropanol, n-butanol, dichloromethane, n-hexane, hexamethylene One or more combination, preferred solvent of the present invention is tetrahydrofuran and alcohol mixed solvent.
CN201711254533.2A 2017-11-27 2017-11-27 A kind of shellfish Qu Shaban intermediate Ns(5- chloro-2-pyridyls)- 2-(4- cyanobenzoyls)Amino ] -5- methoxy benzamides preparation method Pending CN107868039A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201711254533.2A CN107868039A (en) 2017-11-27 2017-11-27 A kind of shellfish Qu Shaban intermediate Ns(5- chloro-2-pyridyls)- 2-(4- cyanobenzoyls)Amino ] -5- methoxy benzamides preparation method

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN201711254533.2A CN107868039A (en) 2017-11-27 2017-11-27 A kind of shellfish Qu Shaban intermediate Ns(5- chloro-2-pyridyls)- 2-(4- cyanobenzoyls)Amino ] -5- methoxy benzamides preparation method

Publications (1)

Publication Number Publication Date
CN107868039A true CN107868039A (en) 2018-04-03

Family

ID=61755078

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201711254533.2A Pending CN107868039A (en) 2017-11-27 2017-11-27 A kind of shellfish Qu Shaban intermediate Ns(5- chloro-2-pyridyls)- 2-(4- cyanobenzoyls)Amino ] -5- methoxy benzamides preparation method

Country Status (1)

Country Link
CN (1) CN107868039A (en)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109180573A (en) * 2018-09-17 2019-01-11 珠海润都制药股份有限公司 A kind of preparation method of betrixaban intermediate
CN115057854A (en) * 2022-04-19 2022-09-16 河北常山生化药业股份有限公司 Preparation method of Alvatripopa maleate intermediate

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101304971A (en) * 2005-11-08 2008-11-12 米伦纽姆医药公司 Pharmaceutical salts and polymorphs of n- (5-chl0r0-2-pyridinyl) -2- [ [4- [ (dimethylamino) iminomethyl] benzoyl] amino] -5-meth oxy-benzamide, a factor xa inhibitor
CN102066384A (en) * 2008-04-23 2011-05-18 百时美施贵宝公司 Quinuclidine compounds as alpha-7 nicotinic acetylcholine receptor ligands
CN102762538A (en) * 2009-12-17 2012-10-31 米伦纽姆医药公司 Methods of synthesizing factor xa inhibitors
CN106518758A (en) * 2015-09-11 2017-03-22 扬子江药业集团江苏紫龙药业有限公司 Preparation method of Betrixaban intermediate N-(5-chloro-2-pyridyl)-2-(4-cyanobenzeneformamido)-5-metoxybenzamide
CN106831553A (en) * 2015-09-11 2017-06-13 天津科伦药物研究有限公司 The preparation method of betrixaban or its analog
WO2017192304A1 (en) * 2016-05-02 2017-11-09 Inception 1, Inc. Arylcarboxamides and uses thereof

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101304971A (en) * 2005-11-08 2008-11-12 米伦纽姆医药公司 Pharmaceutical salts and polymorphs of n- (5-chl0r0-2-pyridinyl) -2- [ [4- [ (dimethylamino) iminomethyl] benzoyl] amino] -5-meth oxy-benzamide, a factor xa inhibitor
CN102066384A (en) * 2008-04-23 2011-05-18 百时美施贵宝公司 Quinuclidine compounds as alpha-7 nicotinic acetylcholine receptor ligands
CN102762538A (en) * 2009-12-17 2012-10-31 米伦纽姆医药公司 Methods of synthesizing factor xa inhibitors
CN106518758A (en) * 2015-09-11 2017-03-22 扬子江药业集团江苏紫龙药业有限公司 Preparation method of Betrixaban intermediate N-(5-chloro-2-pyridyl)-2-(4-cyanobenzeneformamido)-5-metoxybenzamide
CN106831553A (en) * 2015-09-11 2017-06-13 天津科伦药物研究有限公司 The preparation method of betrixaban or its analog
WO2017192304A1 (en) * 2016-05-02 2017-11-09 Inception 1, Inc. Arylcarboxamides and uses thereof

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
ZONGJIE GAN ET AL.: "Convenient chlorination of some special aromatic compounds using N-chlorosuccininide", 《SYNTHESIS》 *
况羽等: "贝曲西班的改进合成", 《化学通报》 *
荣国斌等: "《高等有机化学》", 31 October 2007, 华南理工大学出版社 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109180573A (en) * 2018-09-17 2019-01-11 珠海润都制药股份有限公司 A kind of preparation method of betrixaban intermediate
CN115057854A (en) * 2022-04-19 2022-09-16 河北常山生化药业股份有限公司 Preparation method of Alvatripopa maleate intermediate

Similar Documents

Publication Publication Date Title
AU2004247559B2 (en) Benzamide derivative or salt thereof
JP5588506B2 (en) Method for synthesizing 3- (substituted dihydrogenisoindoleketone-2-yl) -2,6-piperidinedione and its intermediate
KR102593431B1 (en) PROCESSES AND INTERMEDIATES IN THE PREPARATION OF C5aR ANTAGONISTS
CA2620414A1 (en) Benzodiazepine and benzopiperazine analog inhibitors of histone deacetylase
CN108383749A (en) The synthetic method and its intermediate of A Palu amine
WO2019075976A1 (en) Method for preparing roxatidineacetatehydrochloride and intermediate thereof
CN107868039A (en) A kind of shellfish Qu Shaban intermediate Ns(5- chloro-2-pyridyls)- 2-(4- cyanobenzoyls)Amino ] -5- methoxy benzamides preparation method
CN107235957A (en) A kind of synthetic method for preparing Niraparib
CN104650045A (en) Preparation method of avanafil
CN107973784B (en) Synthesis method of fimasartan
CN103923080A (en) Method for preparing antithrombotic drug apixaban
CN103864773B (en) Razaxaban and its preparation method of intermediate
CN105358529B (en) A kind of new method of synthesis Eliquis important intermediate
CN103864772A (en) Preparation method for rivaroxaban and intermediate thereof
CN105175331A (en) Preparation method for EGFR molecule targeting antitumor drug
CN103497146A (en) 2-(N-alkyl piperidinol-4-amino)-4-(substituent phenol) benzene ring derivative as well as preparation method and application thereof
CN104059016A (en) Intermediate for preparing tofacitinib and preparation method of intermediate
CN115557823B (en) A method for synthesizing amide compounds
WO2022262548A1 (en) Preparation method for compound fasudil hydrochloride
CN106892863A (en) The preparation method of vismodegib and its intermediate
CN107935909B (en) Synthesis method of nintedanib and intermediate thereof
CN109879805B (en) Preparation method of apatinib
CN108794375A (en) A kind of pabishta intermediate and its synthesis and application
CN103012256B (en) Method for synthesizing roflumilast
CN109803954B (en) Preparation method of nintedanib and intermediate thereof

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
WD01 Invention patent application deemed withdrawn after publication
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20180403